Aura Biosciences, Inc. (AURA)
NASDAQ: AURA · Real-Time Price · USD
6.28
-0.05 (-0.79%)
Jun 4, 2025, 1:38 PM - Market open
Aura Biosciences Stock Forecast
Stock Price Forecast
According to 5 professional analysts, the 12-month price target for Aura Biosciences stock ranges from a low of $19 to a high of $25. The average analyst price target of $22.6 forecasts a 259.87% increase in the stock price over the next year.
Price Target: $22.60 (+259.87%)
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for Aura Biosciences stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Dec '24 | Jan '25 | Feb '25 | Mar '25 | Apr '25 | May '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 2 | 2 | 2 | 2 | 2 | 3 |
| Buy | 2 | 2 | 2 | 2 | 2 | 2 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 4 | 4 | 4 | 4 | 4 | 5 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Initiates $22 | Strong Buy | Initiates | $22 | +250.32% | May 28, 2025 |
| JMP Securities | JMP Securities | Buy Reiterates $19 | Buy | Reiterates | $19 | +202.55% | May 23, 2025 |
| Citizens Capital Markets | Citizens Capital Markets | Buy Maintains $21 → $19 | Buy | Maintains | $21 → $19 | +202.55% | Mar 26, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Maintains $22 → $25 | Strong Buy | Maintains | $22 → $25 | +298.09% | Mar 25, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $22 | Strong Buy | Reiterates | $22 | +250.32% | Mar 24, 2025 |
Financial Forecast
Revenue This Year
n/a
from 144.86M
Revenue Next Year
n/a
EPS This Year
-2.20
from -1.75
EPS Next Year
-2.35
from -2.20
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | n/a | n/a | 36.8M | ||
| Avg | n/a | n/a | 20.5M | ||
| Low | n/a | n/a | n/a |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | - | - | - | ||
| Avg | - | - | - | ||
| Low | - | - | - |
EPS Forecast
| EPS | 2025 | 2026 | 2027 |
|---|---|---|---|
| High | -1.89 | -1.94 | -1.72 |
| Avg | -2.20 | -2.35 | -2.50 |
| Low | -2.47 | -2.67 | -3.53 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 |
|---|---|---|---|
| High | - | - | - |
| Avg | - | - | - |
| Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.